OTHER × Lymphoma, B-Cell, Marginal Zone × Bortezomib × Clear all Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
Phase NA Completed
23 enrolled 8 charts
VCR
Phase 2 Completed
24 enrolled 11 charts
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Phase 2 Completed
21 enrolled 10 charts
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Phase 1/2 Completed
79 enrolled 19 charts
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase 2 Terminated
5 enrolled 10 charts
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 1 Completed
18 enrolled
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
Phase NA Terminated
3 enrolled 6 charts
BOMB-THROW
Phase 2 Unknown
15 enrolled
COMBOSTAT
Phase 2 Withdrawn
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
Phase 2 Terminated
10 enrolled 7 charts
VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy
Phase 2 Terminated
12 enrolled
Velcade in MALT Lymphoma Patients
Phase 2 Completed
16 enrolled
Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Completed
15 enrolled
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
Phase 1/2 Completed
107 enrolled
PS-341 in Treating Patients With Advanced Cancer
Phase 1 Completed
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
Phase 2 Completed
27 enrolled
VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy
Phase 2 Completed
33 enrolled